Bioreactor and Thiel Cadaver-based Feasibility Evaluations of a Novel Magnesium Wireform Bioresorbable Vascular Scaffold

S-Bahn Medical是一家位于苏格兰格拉斯哥的医疗器械公司，他们正在开发一种生物可吸收血管支架（BVS）或可吸收支架，用于治疗动脉粥样硬化。动脉粥样硬化的发生是由于动脉中斑块的积累导致动脉狭窄，减少了进出心脏的血液流量。这种情况通常被称为心血管疾病（CVD）。自20世纪80年代以来，这种血管管腔狭窄已经可以通过微创、导管为基础的医疗设备技术来治疗，这些技术可以将狭窄的血管管腔扩大到其原始直径。随着时间的推移，这些方法通过新型支架的发展在治疗动脉硬化方面取得了显著的进展。S-Bahn Medical目前的BVS是改善这些治疗的下一步。与传统支架不同，生物可吸收血管支架（BVS）在最初为扩张的血管提供所需的机械支持后会溶解在体内。传统的支架不能被吸收，随着时间的推移会对病人的健康有害。近年来，这一新兴技术取得了一些成功和发展。然而，与传统的不可吸收支架相比，这些BVS设计中的一些关键问题限制了它们治疗患者的有效性。S-Bahn Medical的概念BVS解决了这些设计限制，以改善英国和世界各地心血管疾病的整体治疗。在Innovate UK的资助下，S-Bahn Medical将与Golden Jubilee National Hospital合作，对他们的设备进行首次体外和尸体研究。”

"S-Bahn Medical is a medical device company based in Glasgow, Scotland who are developing a Bioresorbable Vascular Scaffold (BVS) or resorbable stent for the treatment of atherosclerosis. Atherosclerosis occurs due to the accumulation of plaque in an artery causing it to narrow and reduce blood flow to and from the heart. This condition is commonly referred to as Cardiovascular Disease (CVD). Since the 1980's such narrowing of vessel lumen has been treatable by minimally invasive, catheter based medical device technologies that expand the narrowed vessel lumen to its native diameter. Over time these methods have developed significantly in their effectiveness to treat arteriosclerosis through new stent developments. S-Bahn Medical's current BVS is the next step in improving these treatments. Unlike conventional stents, bioresorbable vascular scaffolds (BVS) will dissolve in the body after initially providing the needed mechanical support to the expanded vessel. Conventional stents cannot resorb, and over time can become detrimental to patient health. In recent years there has been some success and development in this emerging technology. However, some key issues in these BVS designs have limited their effectiveness to treat patients compared to conventional non-resorbable stents. S-Bahn Medical's concept BVS, address these design limitations to improve overall treatment of Cardiovascular Disease in the UK and across the world.With the Innovate UK funding, S-Bahn Medical will carry out their first in vitro and cadaver studies of their device in collaboration with the Golden Jubilee National Hospital."